Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31323238 | 0.85 | KEAP1 (0.58) | KEAP1OPRM1OPRD1OPRK1 | |
| SCHEMBL30364917 | 0.84 | OPRM1 (0.61) | OPRM1OPRD1SLC6A2OPRK1 | |
| SCHEMBL14549924 | 0.84 | KEAP1 (0.56) | KEAP1OPRM1OPRD1SLC6A2OPRK1 | |
| SCHEMBL30163250 | 0.84 | KEAP1 (0.56) | KEAP1OPRM1OPRD1SLC6A2OPRK1 | |
| SCHEMBL11997748 | 0.84 | KEAP1 (0.56) | KEAP1OPRM1OPRD1SLC6A2OPRK1 | |
| SCHEMBL31020744 | 0.83 | SLC6A2 (0.63) | OPRM1OPRD1SLC6A2NTSR1 | |
| SCHEMBL30625026 | 0.82 | OPRM1 (0.64) | OPRM1OPRD1SLC6A2NTSR1 | |
| SCHEMBL29376302 | 0.82 | OPRM1 (0.64) | OPRM1OPRD1SLC6A2NTSR1 | |
| SCHEMBL22342218 | 0.82 | KEAP1 (0.54) | KEAP1 | |
| SCHEMBL29581123 | 0.82 | OPRM1 (0.56) | OPRM1OPRD1SLC6A2OPRK1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003732-A1 | METHOD FOR TREATING CANCER | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230003732-A1 | METHOD FOR TREATING CANCER | GSK3A, GSK3B, GSKIP | KEAP1 1800/4885OPRM1 4056/4885OPRD1 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.